Hepatitis Treatment News : Gilead Reports Promising New Data on Sofosbuvir and GS-5885
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis Treatment News » January 2013


emailprint

January 14, 2013

Gilead Reports Promising New Data on Sofosbuvir and GS-5885

Gilead Sciences has announced promising, newly updated data on its hepatitis C virus (HCV) triple therapy, meaning that the combo of the nucleotide sofosbuvir, the NS5A inhibitor GS-5885 and ribavirin is headed toward imminent regulatory filing, HIVandHepatitis reports. Gilead also provided updates on various studies of sofosbuvir/GS-5885 as a fixed-dose, single-pill combination therapy taken with or without ribavirin for periods ranging between eight and 24 weeks.

In November, Gilead reported preliminary results from its Phase II ELECTRON study of sofosbuvir, GS-5885 and ribavirin in participants with HCV genotype 1 who had previously failed an interferon-based treatment. (This category of hep C patient is particularly difficult to treat.) At the time, three out of nine participants had reached a sustained virologic response four weeks after finishing a 12-week treatment (SVR4, considered a cure). Now Gilead has announced that all nine participants have reached SVR4. Researchers will continue to monitor these patients through SVR12 and SVR24.

Gilead reports that it is on track to submit initial regulatory filing to the Food and Drug Administration (FDA) for approval for sofosbuvir mid-2013 and for the fixed-dose combination in 2014.


To read the HIVandHepatitis report, click here.

To read the Gilead release, click here.

Search: Gilead, sofosbuvir, GS-5885, hepatitis C virus, HCV, hep C, triple therapy, ribavirin, interferon, null responder, genotype 1, single-pill combination therapy, SVR, sustained virologic response, FDA, Food and Drug Administration.


Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)


[Go to top]

Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Should Medicaid limit access to new hep C drugs?
Yes
No


Survey
Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.